Loading news...
Becker Capital Management Inc. lifted its position in Hologic, Inc. (NASDAQ: HOLX) by 20.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 81,755 shares of the medical equipment provider's stock after buying an additional 13,610 shares during the period.
111 Capital cut its holdings in Hologic, Inc. (NASDAQ: HOLX) by 43.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 9,077 shares of the medical equipment provider's stock after selling 7,008 shares during the period. 111 Capital's holdings in Hologic were worth $613,000 at
GE HealthCare is gaining ground with strong backlog, AI-driven imaging advances and rising service capture, while Hologic's buyout caps near-term upside.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Citigroup Inc. decreased its holdings in shares of Hologic, Inc. (NASDAQ: HOLX) by 13.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,136,662 shares of the medical equipment provider's stock after selling 170,451 shares during the period. Citigroup Inc. owned approximately 0.51% of
Hologic, Inc. (NASDAQ: HOLX - Get Free Report)'s share price reached a new 52-week high on Friday. The stock traded as high as $75.39 and last traded at $75.3550, with a volume of 703846 shares trading hands. The stock had previously closed at $75.14. Wall Street Analysts Forecast Growth HOLX has been the subject of
Insights from the Fourth Quarter 2025 13F Filing Joel Greenblatt (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providin
HOLX's $18.3B Blackstone-TPG buyout nears close after Q1 miss. With shares near a $76 cash offer, the upside for HOLX investors looks dim.
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Twin Capital Management Inc. decreased its position in Hologic, Inc. (NASDAQ: HOLX) by 77.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,337 shares of the medical equipment provider's stock after selling 18,345 shares during the quarter. Twin
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio.
Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.03 per share a year ago.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2026.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.